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Conservative treatment to slow deterioration of renal function: deterioration of renal function has been complicated by
Evidence-based recommendations. Despite current specific the lack of a single simple, accurate, reproducible, nonin-
therapy, progressive deterioration of renal function in patients vasive method of reliably assessing glomerular filtrationwith primary glomerulonephritis occurs. Nonspecific renopro-
rate (GFR) in human subjects. The rate of deteriorationtective interventions that have been studied include blood pres-
of renal function is not a constant across all patients orsure control, antihypertensive medications, and protein-
restricted diets. To prepare this article, a MEDLINE search all glomerular diseases, and often shows a nonspecific
was conducted, followed by secondary and tertiary searches. “clinic effect” when the patient is enrolled in a study.
Research papers were assessed for level of evidence, and
Also, analysis is complicated by the interaction of inter-graded recommendations were formulated. Protein-restricted
ventions such as reduction of blood pressure (BP) as adiets (to 0.4 to 0.6 g/kg/day) are not recommended for all
patients with reduced renal function (grade A). Very low- consequence of a change in diet, and hence, it may not
protein diets of 0.4 g/kg/day should be considered for patients be possible to assess statistically the relative impact of
with severe renal dysfunction (serum creatinine of more than each factor. Another concern is that it may not be not
350 mmol/liter; grade A). However, there are concerns about
acceptable to generalize the results of studies to all pa-recommending these diets for all patients because of the poten-
tient populations, and attention must be paid to the un-tial for long-term negative outcomes such as nutritional defi-
ciencies. Target blood pressure for persons with proteinuria of derlying diseases that resulted in the initial damage to
more than 1 g/day should be less than 125/75 mm Hg [mean the kidneys.
arterial pressure (MAP) , 92 mm Hg; grade C]. For persons In grading study reports for levels of evidence, studieswith proteinuria of less than 1 g/day, the target blood pressure
using renal death, as measured by the need for dialysis,should be approximately MAP 98 mm Hg (less than 130/80;
grade C). Angiotensin-converting enzyme inhibitor (ACEI) the rate of deterioration, or increase in serum creatinine
therapy is recommended in preference to placebo, conven- levels, were considered “level 1” evidence. The use of
tional, or b-blocker therapy for renoprotection (grade A). surrogate end points such as proteinuria provides level
ACEI therapy cannot be recommended above calcium channel
2 evidence. Subgroup analyses are graded as “level 3.”blockers in patients with nondiabetic renal disease (grade A).
There are uncontrolled or confounding variables that
may influence the outcome of any intervention trial. The
clinic effect was described by Bergstro¨m et al in 1986Following a partial loss of renal function for whatever
[2]. Patients were being followed in a clinic as part of areason, adaptations take place to provide the maximum
study on bone disease. Without any specific intervention,filtration possible from the remaining glomeruli. Al-
both the blood pressure (BP) and the rate of deteriora-though this may seem to be a reasonable and valuable
tion of renal function were noted to decrease. This clinicresponse, this hyperfiltration may lead to “overwork”
effect is a confounding factor and may disrupt statisticaland ultimate loss of the remaining nephrons. This is,
assumptions on which sample sizes were calculated, andin part, believed to be the result of nonimmunological
may undermine the power of a negative study.factors, including intraglomerular hypertension and
hyperfiltration, abnormal flux of proteins through the
mesangial areas, and factors associated with interstitial METHODS
fibrosis [1].
A MEDLINE search was conducted using chronic re-Assessment of the effect of an intervention on the
nal failure, prevention, therapy, BP, hypertension, diet,
and cholesterol as key words. Secondary searches were
done from review and research articles and from per-Key words: progressive renal disease, glomerulonephritis, blood pres-
sure, renoprotection, protein diets, malnutrition. sonal files. Articles were graded for the level of evidence
according to the guidelines generated and used by 1999 by the International Society of Nephrology
S-17
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Table 1. Protein restricted diets
Author Diet
[Reference] Trial/duration g/kg body wt/day N Outcome P value Comments
Level 1
Rosman [7, 8] RCT/ 0.4 for .30 ml/min 228 25% inc SCr ,0.005
18 months 0.6 for 10–30 ml/min
Locatelli [9] RCT/2 years 0.6 vs. 1.0a 456 ESRF only for SCr Excluded nephrotic patients
222–422
Ihle [10] RCT/ 0.4 vs. 0.75 64 ESRF ,0.05 No ACEI allowed
18 months
SCr .350
Klahr [11] RCT/
2.2 years
Study 1 1.3 vs. 0.58 585 change in NS 44% given ACEI. Best
GRF/time response in nephrotic
Study 2 0.58 vs. 0.28 1EAA 255 change in 0.07 32–39% given ACEI
GFR/time
Williams [12] RCT/ .0.8 vs. 0.6 93 1/SCr NS
19 months
Level 3
Maschio [4] case control/ 0.6 vs. 1.0 75 1/SCr ,0.01
max 6 years
Barsotti [5] case control/ 0.5 vs. 0.8 39 CCr descriptive
max 3 years
Level 5
El Nahas [6] self-control/ 0.5 39 1SCr ,0.05
6 months
Abbreviations are: RCT, randomized controlled trial; SCr, serum creatinine; ESRF, end-stage renal failure; ACEI, angiotensin converting enzyme inhibition; GFR,
glomerular filtration rate; EAA, essential amino acid; CCr, creatinine clearance; max, maximum; NS, not significant.
the Canadian Hypertension Society. Recommendations months of follow-up [7]; a second report was made in
were developed to reflect the highest level of evidence 1989, which included 20 additional patients and pro-
available [3]. longed follow-up to 36 to 48 months [8]. In this study,
228 patients were stratified according to gender, age, and
incoming renal function. Study PRDs were 0.6 g/kg/day
RECOMMENDATIONS for those with a creatinine clearance (CCr) greater than
Protein-restricted diets 30 ml/min and 0.4 g/kg/day for those with CCr 10 to 30
ml/min. The control patients in each stratum continuedRecommendation 1. Protein-restricted diets (PRDs)
their usual diet. Sample size was estimated prospectively,cannot be recommended for all patients with renal dis-
with the primary end point being a 25% increase in serumease (grade A).
creatinine concentration. The most common underlyingRecommendation 2. PRDs should be considered for
renal diseases were glomerular diseases (33.3%), neph-patients with severe renal impairment (serum creatinine
rosclerosis (11.1%), and analgesic nephropathy (10.5%).of more than 350 mmol/liter; grade A). However, there
Overall, PRDs were beneficial, with the greatest benefitis concern that such a restrictive diet may not be nutri-
for the group with the lowest renal function (level 1tionally sufficient, and there is conflicting evidence on
evidence). Using the data from the minimum of three-the ability of patients to adhere to a very low protein
years follow-up, the rate of deterioration was reduceddiet.
by 50% or more. There were fewer survivors in theEvidence. In the 1960s, when chronic renal dialysis
control group for the strata that started with a CCr of 10was not readily available, very low-protein diets were
to 30 ml/min, but there was no difference in survivorsused as a means to reduce uremic symptoms. Used in
seen in the strata with an initial CCr of more than 30this way, they are effective. The first reports examining
ml/min. Subgroup analysis demonstrated a benefit forthe effect of PRDs on the deterioration of renal function
patients with glomerulonephritis but not for any otherwere from studies in which the diets were instituted as
specific diseases (level 3 evidence). Although no effecta means to reduce renal osteodystrophy [2, 4]. Retro-
of gender was noted in the first article, it was later re-spective studies [4–6] and prospective studies [7–12] are
ported that renal function deteriorated faster in menpresented in Table 1 and have recently been the subject
than in women and that PRDs slowed the rate of deterio-of a meta-analysis [13].
ration in men but not in women. Age was also a factorThe first prospective randomized controlled trial (level
1 study) was reported in 1984 by Rosman et al after 18 in that renal function deteriorated faster in persons less
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than 41 years. This age group had a significantly greater tients were stratified into two groups depending on initial
GFR: study 1, GFR 25 to 55 ml/min, N 5 585 (meannumber of patients with glomerulonephritis and fewer
cases of nephrosclerosis and interstitial nephritis. How- serum creatinine level 165 mmol/liter, estimated serum
creatinine levels of 106 to 211 mmol/liter); study 2, GFRever, the effect of PRDs was not different between the
two age groups. Rosman et al stated that for patients 13 to 24 ml/min, N 5 255 (mean serum creatinine level
299 mmol/liter, estimated serum creatinine levels of 212with polycystic kidney disease (PKD; 6.1% of the patient
sample), PRDs had no effect, and the deterioration of to 616 mmol/liter). In study 1, patients were randomized
to a control diet or a PRD (1.3 vs. 0.58 g/kg/day, respec-renal function was related to diastolic BP (DBP; r 5
20.88, P , 0.001) [7]. tively) and then to usual BP vs. low BP [mean arterial
pressure (MAP) 107 vs. 92 mm Hg]. In study 2, patientsNutritional status was assessed using measurements
of body weight and serum parameters such as proteins were randomized to either a low-protein diet (0.58 g/kg/
day) or a very low protein plus EAAs (0.28 g/kg/day)and amino acids. A significant reduction in urinary creati-
nine excretion in the group receiving 0.4 mg/kg/day pro- and then to normal BP or low-BP groups. Patients were
followed for a mean of 2.2 years. The primary end pointtein was noted at the three-month visit and persisted for
the rest of the study. This may have been a reflection of was the rate of decline in GFR. Approximately 25% of
the patients had primary glomerular diseases, whereasa loss of muscle mass or a reduced protein intake. Plasma
concentrations of essential amino acids (EAAs) and 24% had PCKD. In study 1, there was a significant reduc-
tion in GFR in the first four months, which was thoughtnonessential amino acids are known to decrease in con-
junction with progressive renal disease. Rosman et al to be the result of the hemodynamic effect of protein
restriction on GFR. Thereafter, the rate of decline inreported that there was no difference in any of the amino
acids between the control and PRD groups, although GFR was slower than it had been in the first four months,
but was not different between the normal and low-pro-the levels of some amino acids were reduced compared
with normal ranges [7]. tein diet. There was no difference in the rate of decline
in the normal versus low-BP groups. A more detailedIn 1991, Locatelli reported a level 1 study in which
456 patients were stratified according to renal dysfunc- examination of the effect of the PRDs demonstrated that
adherence to the PRDs was not optimal, with the meantion into one of three groups [group A, plasma creatinine
of 133 to 221 mmol/liter (N 5 216); group B, plasma protein intake in the control group being lower than
prescribed (1.11 vs. 1.3 g/kg/day) and it being greater increatinine of 222 to 442 mmol/liter (N 5 187); group C,
plasma creatinine of 443 to 619 mmol/liter (N 5 53)], the PRD (0.77 vs. 0.58 g/kg/day). In study 2, there was
a trend toward a difference in the rate of decline betweenand then randomized to control diet (1.0 g/kg/day) or
the study PRDs (0.6 g/kg/day) [10]. The primary end the PRD groups; the follow-up article detailed the lack
of significant difference in total protein intake in the twopoints were a doubling of serum creatinine level or the
need for dialysis. Patients were followed for two years. diet arms [14]. Using actual protein intake rather than
prescribed intake, there was no correlation betweenComparing the collective groups, there was a trend to
fewer end points in the PRD group (P , 0.06). In exam- GFR decline and actual protein intake. No measure-
ments of nutritional deficiency were reported.ining the three stratified groups individually, there was
a significant benefit only in group B (serum creatinine Ihle et al reported a level 1 study in which 64 patients
with a serum creatinine level of more than 350 mmol/222 to 422 mmol/liter; level 1 evidence). Assessment of
disease-specific groups showed no difference for patients liter were randomized to a control diet (more than 0.75
g/kg/day) or a PRD (0.4 g/kg/day) and were followedwith glomerulonephritis (N 5 132), tubulointerstitial ne-
phropathy (N 5 155), or PKD (N 5 74); however, there for 18 months [9]. The primary outcome variable was
end-stage renal failure (ESRF). More patients in thewas a trend to significance for nephroangiosclerosis (N 5
72, P , 0.08). Dietary compliance for the control group control group (9 out of 33 control patients) than in the
PRD group (2 out of 31 PRD patients) developed ESRFwas good, but there was a median excess intake of dietary
protein of approximately 40% in the PRD groups. In (P , 0.05) in the last three months of the study. GFR
fell in the control group (0.25 6 0.03 ml/second) but notconclusion, there was no consistent evidence of benefit,
but this could have been due to poor compliance in in PRD group (P , 0.01), and serum creatinine levels
increased more in the control group than in PRD groupthe PRD group. Also, patients with nephrotic syndrome
were excluded; this group of patients may benefit the (P , 0.02). A total of five patients was withdrawn from
the study for noncompliance. In patients with signifi-most because the rate of deterioration is related to the
level of proteinuria. cantly reduced renal function, a PRD of 0.4 g/kg/day was
effective in slowing the rate of deterioration of renalThe Modification of Diet in Renal Disease (MDRD)
Study Group reported their initial article in 1994 [11]. dysfunction and was associated with fewer patients re-
quiring dialysis over 18 months. These results are consis-This has been followed by articles with more inclusive
analyses and discussions of the effects of diet [14]. Pa- tent with those reported by Rosman et al [7, 8] for the
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group with the lowest initial renal function. No data on of less than 130/80 mm Hg (MAP 98) is recommended
(grade C).nutritional status were reported.
Evidence. As described earlier, a retrospective cohort
study suggests that the target DBP be at or below 90
BLOOD PRESSURE MANAGEMENT mm Hg [15]. It is theoretically possible that lowering BP
The clinical association of hypertension and renal dis- too low could result in reduced renal blood flow and
ease is common. However, it is not always clear if hyper- GFR caused by impaired autoregulation. Prospective
tension is the cause or the result of the renal disease or studies with small sample sizes [17–20] were not ade-
if it is a coexisting condition. In the development of quately powered to discern optimal target BP for reno-
evidence-based guidelines for the management of hyper- protection (Table 2).
tension in patients with renal disease, three issues were As described earlier, the MDRD was designed to as-
explored: (a) the correlation between the reduction in sess the effect of different target BP [11, 21]. In study
BP and preservation of renal function, (b) the target BP 1, there was no difference in the rate of decline in the
that confers maximum benefit, and (c) the medications two BP groups (level 1). Subgroup analysis showed bene-
to use to attain that BP. fit for persons with Uprotein of more than 1 g/day, and
more so if Uprotein was more than 3 g/day (level 3). An
examination of the relationship of achieved BP and de-Correlation between blood pressure reduction and
cline of glomerular filtration rate (GFR) [21] demon-renal preservation
strated that GFR declined significantly faster if MAP of
Recommendation 3. Hypertension [diastolic blood more than 92 in patients with a Uprotein of more than 3
pressure (DBP) more than 90 mm Hg] in patients with g/day; for patients with lesser Uprotein, the BP threshold
renal disease should be treated in order to slow the rate was a MAP of 98 mm Hg. In study 2, there was also
of deterioration of renal function (grade D). no difference in the two BP groups (level 1); subgroup
Evidence. A correlation between control of BP and analysis again demonstrated that patients with Uprotein of
a slowing of the deterioration of renal function was noted more than 1 g/day benefited from the more aggressive
in a prospective study in which patients were being fol- BP reduction. A MAP of approximately 92 mm Hg was
lowed for other reasons (level 5) [2]. A retrospective the breakpoint for patients with a Uprotein of more than
cohort study of 200 patients examining the relationship 1 g/day, but tight BP control did not appear to alter the
between BP and the rate of deterioration of renal func- rate of deterioration for patients with no proteinuria.
tion described a breakpoint for DBP of 90 mm Hg, below In the MDRD study, 25% of patients had proven
which the deterioration of renal function was signifi- primary glomerular disease, and 24% had PKD. Sub-
cantly slower (level 5) [15]. The threshold of 90 mm DBP group analyses by renal disease were not reported. A
was also noted when the course of individual patients high degree of proteinuria is more likely to be seen in
was examined prereduction and postreduction of DBP patients with primary glomerular disease, as opposed to
to less than 90 mm Hg (level 4). The authors did not find PKD or interstitial renal diseases. If this assumption is
a consistent relationship between systolic blood pressure correct, patients with glomerular diseases may gain more
(SBP) and the rate of deterioration of renal function. In benefit from tight BP control than patients with intersti-
another report, the rate of rise of serum creatinine level tial or cystic diseases.
was demonstrated to be closely related to DBP: 18.8
Choice of antihypertensive medicationmmol/liter/month in hypertensive patients versus 2.1
mmol/liter/month for normotensive patients (P , 0.001, Recommendation 6. For renoprotection, angiotensin-
level 5) [16]. converting enzyme inhibitor (ACEI) therapy is pref-
Because these data are from descriptive or retrospec- erable to placebo, conventional, or b-blocker therapy
tive studies, evidence for causation would not be consid- (grade A).
ered acceptable because confounding factors cannot be Recommendation 7. ACEI therapy cannot be recom-
controlled. mended in preference to calcium channel blocker therapy
for patients with nondiabetic renal disease (grade A).
Target blood pressure Evidence. Because studies have demonstrated benefit
Recommendation 4. For patients with a GFR of 15 to from control of hypertension regarding prevention of
55 ml/min (estimated serum creatinine level of 106 to cardiovascular events, placebo-controlled studies of hy-
616 mmol/liter) and urinary protein excretion (Uprotein) pertension management in renally impaired patients are
over 1.0 g/day, a target BP of less than 125/75 mm Hg not ethically acceptable. Studies are usually designed to
(MAP less than 92 mm Hg) is recommended (grade C). focus on comparing two drugs, but patients often ulti-
Recommendation 5. For patients with a GFR of 15 to mately receive multiple drugs because control of high
BP in these patients is difficult. Clouding interpretation55 ml/min and proteinuria 0.25 to 1.0 g/day, a target BP
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Table 2. Blood pressure (BP) control in renal insufficiency; Effect of control and target blood pressure
Author
[Reference] Design/duration N BP target Drugs Outcome Result P value
Level 1
Klahr [11] RCT 2.2 years 585 MAP 92 vs. 107 physician decline of No difference NS
discretion GFR
RCT 2.2 years 285 MAP 92 vs. 107 physician decline of No difference NS
discretion GFR
Toto [17] RCT 42 months 87 DBP ,80 vs. enalapril vs. GFR No difference between
85–95 placebo target BP group
Level 3
Klahr [11] RCT 2.2 years 585 MAP 92 vs. 107 physician decline of Benefit if Uprotein .1g/ ,0.05
Sub-group discretion GFR day
analysis
RCT 2.2 years 285 MAP 92 vs. 107 physician decline of Benefit if Uprotein .1g/ ,0.01
Sub-group discretion GFR day
analysis
Level 4
Bauer [9] pre- post-/ 23 DBP ,90 enalapril 6 renal stable renal function
3 years hydrochlor function over 3 years
2 thiazide
Pettinger [19] pre- post-/ 22 DBP ,80 vs. physician GFR SCr stable at both levels of NS
36 months 90–95 discretion DBP
Wight [20] crossover 18 18 3 target ranges physician 1/SCr MAP 83mmHg optimal ,0.05
months discretion
Level 5
Bergstro¨m [2] case series 17 No change BP relates to rise in SCr ,0.02
Brazy [15] case series 200 physician 1/SCr slowest decline if ,0.05
discretion DBP,90
Kes [16] case series 108 compare physician SCr Increase in SCr 2.1 vs. ,0.001
DBP,90 to discretion 18.8 lmol/liter/
DBP .90 month
Abbreviations are: MAP, mean arterial pressure; DBP, diastolic blood pressure; Uprotein, urinary protein; other abbreviations are in Table 1.
of these interventive studies is the heterogeneity of the of serum creatinine (P , 0.001). The overall reduction
in risk was 53% (71% in mild renal insufficiency com-patient sample. Not all patients with renal disease can
be considered to have the same dynamics contributing to pared with 46% in moderate renal insufficiency; level
1). A greater reduction in risk was demonstrated fortheir hypertension or renal deterioration. For example, it
is likely that patients with a primary glomerular disease men, patients with glomerular disease, and those with a
Uprotein of less than 1 g/day (level 3). There was a modestand patients with cystic diseases have intrinsically differ-
ent intrarenal dynamics, but studies have often included difference in attained BP between the groups, but the
results remained significant when this was taken intothem in the same analysis. Where sample size allows,
authors have often commented on subpopulations effect. Paradoxically, there were more deaths (all-cause
mortality) in the treated group (8 out of 300 patients)grouped according to renal disease.
Evidence-based guidelines for the treatment of essen- compared with the placebo-treated group (1 out of 283
patients). This mortality imbalance was not seen in thetial hypertension support the use of diuretics and/or
b-adrenergic blocking agents as the standard of care [22]. Angiotensin-Converting-Enzyme Inhibition in Progres-
sive Renal Insufficiency Study Group extension studyTherefore, these agents have often been the minimum
standard against which other treatments are compared [30]. The recent REIN study comparing ramipril to pla-
cebo in 352 patients also demonstrated a better outcome(Table 3) [23–29]. A large prospective study was reported
by Maschio et al in which 583 patients with serum creati- for ACEI therapy [24]. Follow-up of patients with a
Uprotein of more than 3 g in the REIN study further demon-nine levels between 133 and 354 mmol/liter were followed
for three years, after being randomized to benazepril or strated the protective effect of ACEI (ramipril) even
when BP control is optimal [31].placebo plus standard antihypertensive therapy [23]. End
points were a doubling of serum creatinine level or devel- Angiotensin converting enzyme inhibition therapy has
been demonstrated to be more renoprotective than treat-opment of renal failure, while target DBP was less than
90 mm Hg. After three years, 31 patients on benazepril ment with b-adrenergic blocking drugs [25–29]. Han-
nedouche et al reported a three-year study in which 100and 57 placebo-treated patients had reached doubling
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Table 3. Blood pressure control in renal insufficiency: Drug comparisons to placebo or conventional therapy
Author
[Reference] Design N BP target Drugs Outcome Result P value
Level 1
Maschio [23] RCT 3 years 583 DBP ,90 benazepril vs. 2 3 SCr or ,0.001
standard renal failure
GISEN [24] RCT 5 years 166 DBP ,90 ramipril vs. GFR decline Study stopped at interim ,0.001
standard analysis
Hannedouche [25] RCT 3 years 100 DBP ,90 enalapril vs. b renal survival RR3.5 for beta blocker ,0.05
blocker
Kamper [26] RCT 70 120–140 enalapril vs. GFR Slower fall with enalapril ,0.05
80–90 standard
Ihle [27] RCT 2 years 70 Not stated enalapril vs. 1/SCr CCr GFR Slower decline with ,0.038
placebo enalapril
Toto [17] RCT 42 87 DBP,90 enalapril vs. GFR No difference between
months vs. 85–95 placebo target BP group
Level 2
Praga [28] case series 46 MSP ,116 captopril 1/SCr Protection relates to fall
18 months in Uprotein
Cattran [29] case series 115 CEI vs. CCr Slower fall with CEI 0.01
3–121 standard
months
patients with SCr of 200 to 400 mmol/liter were random- result from rapid control of the BP and allowed for
an easier comparison of the deterioration plots. Thisized to enalapril or a b-blocker (as an example of conven-
tional or standard therapy) [25]. The primary outcome prolonged baseline also permitted a before and after
intrapatient comparison. That paired analysis demon-parameter was renal survival. Despite there being no
difference in mean BP control between the groups, pa- strated that patients had a significantly slower (P , 0.01
for both drug groups) rate of decline in the three-yeartients on b-blocker therapy had an increased relative
risk (RR) of 3.5 for reaching renal death. Also, there prospective arm than in the one-year baseline on conven-
tional therapy (level 4). In the prospective portion ofwas a slower rate of decline in the reciprocal plot 1/SCr
in enalapril-treated patients (P , 0.05). A fall in daily the study, there was no overall difference in any of the
outcomes between the captopril and nifedipine groupsUprotein was seen with enalapril therapy (median dose
enalapril 10 mg) but not with b-blocker therapy. Reduc- (level 1). However, in the final year of the study, there
were more patients with renal death in the nifedipinetion in Uprotein has been reported to predict or correlate
with renoprotection [24, 26, 28]. group than in the captopril group. The presence of only
one study with prolonged follow-up leaves it unclear asThe effectiveness of ACEI therapy compared with
calcium channel blockers has also been examined. An to whether these two classes of antihypertensives have
any different long-term benefit in this special study popu-early report by Brazy et al of a retrospective assessment
of the deterioration of renal function in 200 patients lation.
In summary, there is evidence that reduction in BP isshowed that minoxidil and calcium channel blockers
associated with renoprotection and that the optimal goalwere associated with the best renoprotection [32]. Min-
BP may depend on the degree of proteinuria and theoxidil had been reported in 1976 to be renoprotective,
level of renal function. ACEI therapy is better than pla-but there have not been specific comparative trials be-
cebo, conventional, or b-blocker therapy, but the evi-tween minoxidil and other antihypertensive agents. A
dence suggests that there is no difference between thesmall prospective study by Bianchi et al of 16 patients
long-term renoprotection of ACE inhibitors and calciumcompared nicardipine and enalapril and showed mainte-
channel blockers.nance of renal function over one year with both agents
(level 2) [33].
Lipid-lowering therapyIn the longest comparative study, 142 patients were
randomized to captopril or nifedipine after being fol- Recommendation 8. Lipid-lowering therapy cannot be
recommended for renoprotection because there are in-lowed on conventional antihypertensive therapy for 12
months [34]. Outcomes included the plot of 1/SCr versus sufficient studies.
Evidence. Hyperlipidemia commonly occurs in associ-time, actual renal survival, and CCr over three years (Ta-
ble 4). Therapy was titrated to a target DBP of less than ation with proteinuria greater than 3.0 g/day. The accel-
erated atherosclerosis seen in patients with nephrotic95 mm Hg. The initial year of conventional BP therapy
eliminated the early reduction in renal function that can syndrome is thought to be partly a result of the hyperlip-
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Table 4. Blood pressure control in renal insufficiency: comparative drug trials
Author BP target
[Ref] Design N mm Hg Drugs Outcome Result P value
Level 1
Zucchelli [33] RCT 3 years 142 DBP,95 captopril vs. nifedipine Renal No difference in all NS
survival outcomes
1/SCr CCr
Bianchi [32] RCT 52 16 enalapril vs. nicardipine SCr No change NS
weeks
Level 4
Zucchelli [33] pre- post- 51 DBP,95 captopril vs. standard 1/SCr Slower fall with ,0.01
(Level 4) captopril
pre- post- 50 DBP,95 nifedipine vs. standard 1/SCr Slower fall with ,0.01
(Level 4) nifedipine
idemia, but long-term intervention studies assessing the fibrate was associated with significant toxicity in patients
with reduced renal function. Although serious adversepotential benefit of lipid-lowering effect have not been
conducted. The exact mechanism of the often extreme events have not been reported in the small randomized
trials, there are concerns that toxicity could be a problemelevations of serum cholesterol levels is unclear [35],
and it is not known why some patients with significant with the use of the newer lipid-lowering agents. The
use of combinations of lipid-lowering drugs, often inproteinuria do not develop hyperlipidemia.
In an analysis of the Helsinki Heart Study in which association with cyclosporine in patients with trans-
men were randomized to placebo or gemfibrozil, serum plants, has been reported to result in significant muscle
creatinine levels increased by 3% over five years in both toxicity and acute renal failure [40–44].
groups. Neither age, smoking status, nor physical activity
influenced this increase, but hypertension did. There was
SUMMARYno association between triglyceride or low-density lipo-
From large trials, the interaction of factors affectingprotein (LDL) levels and the change in serum creatinine,
the rate of deterioration of renal function or those associ-but high-density lipoprotein (HDL) levels were inversely
ated with poor outcome can be appreciated. Heavy pro-related to the change in renal function. Evaluation of
teinuria, hypertension, and initial serum creatinine levelsthe combined contribution of BP and serum cholesterol
are factors that predicted outcome in intervention trials.(SChol) levels demonstrated that the presence of a DBP of
Underlying renal disease is also important; nephro-more than 95 mm Hg and a ratio low density lipoprotein
sclerosis is associated with the slowest deterioration and(LDL)-SChol/high density lipoprotein (HDL)-SChol of more
PKD with the fastest. Patients with glomerular diseasesthan 4.4 was associated with the greatest change in renal
may benefit the most from PRDs and control of hyper-function [36]. However, the men recruited into this study
tension. Serum lipids levels have not been found to behad normal renal function, and therefore, it is unclear
a prognostic factor in human studies.if these results are generalizable to patients with reduced
Protein-restricted diets have limited effectiveness; pa-renal function.
tients with more reduced renal function may benefitIntervention studies in patients with nondiabetic ne-
more from PRDs. BP control is most consistently associ-phropathy and hyperlipidemia have failed to examine
ated with renoprotection, particularly in the presencerenoprotection. Four studies, each with small sample
of significant proteinuria. ACEI therapy appears to besizes (4, 8, 14, and 17 patients, respectively), have demon-
better than conventional therapy or b-blockers at pre-strated that lovastatin is effective in lowering serum cho-
venting the need for dialysis or at least slowing the ratelesterol levels for up to two years without serious adverse
of deterioration of renal function. There is no evidenceeffects and is more effective than diet alone [37–40]. A
that ACEIs are better than calcium channel blockers fordose–response study demonstrated progressively greater
long-term renal preservation.reductions in LDL cholesterol levels (29, 34, and 45%)
on doses of 10, 20, and 40 mg lovastatin daily [40]. How-
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fibrozil and simvastatin have also been demonstrated
1. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature
to be effective lipid-lowering agents for patients with of renal disease progression. Kidney Int 51:2–15, 1997
2. Bergstro¨m J, Alvestrand A, Bucht H, Gutierrez A: Progressionnephrotic syndrome [39, 40]. In the past, the use of clo-
Burgess: Conservative treatment for renal diseaseS-24
of chronic renal failure in man is retarded with more frequent The Modification of Diet in Renal Disease Study. Ann Intern Med
123:754–762, 1995clinical follow-ups and better blood pressure control. Clin Nephrol
22. Ogilvie RI, Burgess ED, Cusson JR, Feldman RD, Leiter LA,25:1–6, 1986
Myers MG: Report of the Canadian Hypertension Society Consen-3. Carruthers SG, Larochelle P, Haynes RB, Petrasovits A,
sus Conference. III. Pharmacologic treatment of essential hyper-Schiffrin EL: Report of the Canadian Hypertension Society Con-
tension. Can Med Assoc J 149:575–584, 1993sensus Conference. I. Introduction. Can Med Assoc J 149:289–293,
23. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Mo-1993
tolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angio-4. Maschio G, Oldrizzi L, Tessitore N, D’Angelo A, Valvo E,
tensin-converting-enzyme inhibitor benazepril on the progressionLupo A, Loschiavo C, Fabris A, Gammaro L, Rugiu C, Panzetta
of chronic renal insufficiency: The Angiotensin-Converting-G: Effects of dietary protein and phosphorus restriction on the
Enzyme Inhibition in Progressive Renal Insufficiency Researchprogression of early renal failure. Kidney Int 22:371–376, 1982
Group. N Engl J Med 334:939–945, 19965. Barsotti G, Morelli E, Giannoni A, Guiducci A, Lupetti S,
24. The GISEN Group (Gruppo Italiano di Studi EpidemiologiciGiovannetti S: Restricted phosphorus and nitrogen intake to slow
in Nefrologia): Randomized placebo-controlled trial of effect ofthe progression of chronic renal failure: A controlled trial. Kidney
ramipril on decline in glomerular filtration rate and risk of terminalInt 24(Suppl 16):S278–S284, 1983
renal failure in proteinuric, non-diabetic nephropathy. Lancet6. El Nahas AM, Masters-Thomas A, Brady SA, Farrington K,
349:1857–1863, 1997Wilkinson V, Hilson AJ, Varghese Z, Moorhead JF: Selective
25. Hannedouche T, Landais P, Goldfarb B, el Esper N, Fourniereffect of low protein diets on chronic renal diseases. BMJ 289:1337–
A, Godin M, Durand D, Chanard J, Mignon F, Suo JM, Gru¨n-1341, 1984
feld J-P: Randomised controlled trial of enalapril and beta block-7. Rosman JB, ter Wee PM, Meijer S, Piers-Becht TP, Sluiter WJ,
ers in non-diabetic chronic renal failure. BMJ 309:833–837, 1994Donker AJ: Prospective randomized trial of early dietary protein
26. Praga M, Hernandez E, Montoyo C, Andres A, Ruilope LM,restriction in chronic renal failure. Lancet 2:1291–1296, 1984
Rodicio JL: Long-term beneficial effects of angiotensin-converting8. Rosman JB, Langer K, Brandl M, Piers-Becht TP, van der Hem
enzyme inhibition in patients with nephrotic proteinuria. Am JGK, ter Wee PM, Donker AJ: Protein-restricted diets in chronic
Kidney Dis 20:240–248, 1992renal failure: A four-year follow-up shows limited indications. Kid-
27. Kamper AL, Strandgaard S, Leyssac PP: Effect of enalapril onney Int 36(Suppl 27):S96–S102, 1989
the progression of chronic renal failure: A randomized controlled9. Ihle BU, Becker GJ, Whitworth JA, Charlwood RA, Kincaid-
trial. Am J Hypertens 5:423–430, 1992Smith PS: The effect of protein restriction on the progression of
28. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smithrenal insufficiency. N Engl J Med 321:1773–1777, 1989
PS, Becker GJ: Angiotensin-converting enzyme inhibition in non-10. Locatelli F, Alberti D, Graziani G, Buccianti G, Redaelli B,
diabetic progressive renal insufficiency: A controlled double-blindGiangrande A: Prospective, randomized, multicentre trial of ef-
trial. Am J Kidney Dis 27:489–495, 1996fect of protein restriction on progression of chronic renal insuffi-
29. Cattran DC, Greenwood C, Ritchie S: Long-term benefits ofciency: Northern Italian Cooperative Study Group. Lancet 337:
angiotensin-converting enzyme inhibitor therapy in patients with1299–1304, 1991 severe immunoglobulin a nephropathy: A comparison to patients11. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek receiving treatment with other antihypertensive agents and to pa-
JW, Striker G: The effects of dietary protein restriction and blood- tients receiving no therapy. Am J Kidney Dis 23:247–254, 1994
pressure control on the progression of chronic renal disease: Modi- 30. Locatelli F, Carbarns IRI, Maschio G, Mann JFE, Ponticelli
fication of Diet in Renal Disease Study Group. N Engl J Med C, Ritz E, Alberti D, Motolese M, Janin G, Zucchelli P, and
330:877–884, 1994 the Angiotensin-Converting-Enzyme Inhibition in Progressive
12. Williams PS, Stevens ME, Fass G, Irons L, Bone JM: Failure Renal Insufficiency Study Group: Long-term progression of
of dietary protein and phosphate restriction to retard the rate of chronic renal insufficiency in the AIPRI Extension Study. Kidney
progression of chronic renal failure: A prospective, randomised, Int 52(Suppl 63):S63–S66, 1997
controlled trial. Q J Med 81:837–855, 1991 31. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R,
13. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH: The Remuzzi G, on behalf of Gruppo Italiano di Studi Epidemiol-
effect of dietary protein restriction on the progression of diabetic ogici in Nefrologia (GISEN): Renal function and requirement
and nondiabetic renal disease: A meta-analysis. Ann Intern Med for dialysis in chronic nephropathy patients on long-term ramipril:
124:627–632, 1996 REIN follow-up trial. Lancet 352:1252–1256, 1998
14. Levey AS, Adler S, Caggiula AW, England BK, Greene T, 32. Brazy PC, Stead WW, Fitzwilliam JF: Progression of renal insuf-
Hunsicker LG, Kusek JW, Rogers NL, Teschan PE: Effects of ficiency: Role of blood pressure. Kidney Int 35:670–674, 1989
dietary protein restriction on the progression of advanced renal 33. Bianchi S, Bigazzi R, Baldari G, Campese VM: Long-term effects
disease in the Modification of Diet in Renal Disease Study. Am of enalapril and nicardipine on urinary albumin excretion in pa-
J Kidney Dis 27:652–663, 1996 tients with chronic renal insufficiency: A 1-year follow-up. Am J
15. Brazy PC, Fitzwilliam JF: Progressive renal disease: Role of race Nephrol 11:131–137, 1991
and antihypertensive medications. Kidney Int 37:1113–1119, 1990 34. Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M,
16. Kes P, Ratkovic-Gusic I: The role of arterial hypertension in Stallone C, Sanna G, Gaggi R: Long-term comparison between
progression of renal failure. Kidney Int 49(Suppl 55):S72–S74, 1996 captopril and nifedipine in the progression of renal insufficiency.
17. Bauer JH, Reams GP, Lal SM: Renal protective effect of strict Kidney Int 42:452–458, 1992
blood pressure control with enalapril therapy. Arch Intern Med 35. Wheeler DC, Bernard DB: Lipid abnormalities in the nephrotic
147:1397–1400, 1987 syndrome: Causes, consequences, and treatment. Am J Kidney Dis
18. Pettinger WA, Lee HC, Reisch J, Mitchell HC: Long-term im- 23:331–346, 1994
provement in renal function after short-term strict blood pressure 36. Manttari M, Tiula E, Alikoski T, Manninen V: Effects of hyper-
control in hypertensive nephrosclerosis. Hypertension 13:766–772, tension and dyslipidemia on the decline in renal function. Hyperten-
1989 sion 26:670–675, 1995
19. Wight JP, Brown CB, El Nahas AM: Effect of control of hyper- 37. Vega GL, Grundy SM: Lovastatin therapy in nephrotic hyperlipid-
tension on progressive renal failure. Clin Nephrol 39:305–311, 1993 emia: Effects on lipoprotein metabolism. Kidney Int 33:1160–1168,
20. Toto RD, Mitchell HC, Smith RD, Lee HC, McIntire D, Pet- 1988
tinger WA: “Strict” blood pressure control and progression of 38. Prata MM, Nogueira AC, Pinto JR, Correia AM, Vicente O,
renal disease in hypertensive nephrosclerosis. Kidney Int 48:851– Rodrigues MC, Miguel MJ: Long-term effect of lovastatin on
859, 1995 lipoprotein profile in patients with primary nephrotic syndrome.
21. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Clin Nephrol 41:277–283, 1994
Hunsicker LG, King AJ, Klahr S, Massry SG, Siefter JL: Blood 39. Chan PC, Robinson JD, Yeung WC, Cheng IK, Yeung HW,
Tsang MT: Lovastatin in glomerulonephritis patients with hyper-pressure control, proteinuria, and the progression of renal disease:
Burgess: Conservative treatment for renal disease S-25
lipidemia and heavy proteinuria. Nephrol Dial Transplant 7:93–99, thy and nephrotic syndrome with simvastatin and diet, versus diet
alone. Clin Nephrol 46:219–224, 19961992
43. Locatelli F, Alberti D, Graziani G, Buccianti G, Redaelli B,40. Golper TA, Illingworth DR, Morris CD, Bennett WM: Lova-
Giangrande A, Marcelli D, Francucci BM: Factors affectingstatin in the treatment of multifactorial hyperlipidemia associated
chronic renal failure progression: Results from a multicentre trial.with proteinuria. Am J Kidney Dis 13:312–320, 1989
The Northern Italian Cooperative Study Group. Miner Electrolyte41. Groggel GC, Cheung AK, Ellis-Benigni K, Wilson DE: Treat- Metab 18:295–302, 1992
ment of nephrotic hyperlipoproteinemia with gemfibrozil. Kidney 44. Maschio G, Oldrizzi L, Rugiu C, Valvo E, Lupo A, Loschiavo
Int 36:266–271, 1989 C, Tessitore N, Fabris A, Gammaro L, Panzetta G: Factors
42. Rayner BL, Byrne MJ, van Zyl Smit R: A prospective clinical affecting progression of renal failure in patients on long-term di-
etary protein restriction. Kidney Int 32(Suppl 22):S49–S52, 1987trial comparing the treatment of idiopathic membranous nephropa-
